NCT01527656View on ClinicalTrials.gov

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

February 29, 2004

Study Completion Date

February 29, 2004

Conditions
DiabetesHealthy
Interventions
DRUG

biphasic insulin aspart 70

A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY